INAF Stock Overview
PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia.
No risks detected for INAF from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||Rp1,165.00|
|52 Week High||Rp3,490.00|
|52 Week Low||Rp1,100.00|
|1 Month Change||-13.70%|
|3 Month Change||-42.61%|
|1 Year Change||-47.76%|
|3 Year Change||-69.34%|
|5 Year Change||-72.26%|
|Change since IPO||468.29%|
Recent News & Updates
|INAF||ID Pharmaceuticals||ID Market|
Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: INAF underperformed the ID Market which returned 15.6% over the past year.
|INAF Average Weekly Movement||4.8%|
|Pharmaceuticals Industry Average Movement||3.7%|
|Market Average Movement||6.3%|
|10% most volatile stocks in ID Market||12.2%|
|10% least volatile stocks in ID Market||3.0%|
Stable Share Price: INAF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: INAF's weekly volatility (5%) has been stable over the past year.
About the Company
PT Indofarma Tbk, together with its subsidiaries, manufactures and markets pharmaceutical products in Indonesia. The company trades in and distributes drugs, medical devices, medical supplies, extracts, and herbals; and operates laboratory. It also provides COVID-19 test services, including rapid diagnostic test antigen; reverse transcription polymerase chain reaction, and genose.
Indofarma Fundamentals Summary
|INAF fundamental statistics|
Is INAF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INAF income statement (TTM)|
|Cost of Revenue||Rp2.46t|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-12.13|
|Net Profit Margin||-1.29%|
How did INAF perform over the long term?See historical performance and comparison
Is Indofarma undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: INAF (IDR1165) is trading above our estimate of fair value (IDR1019.77)
Significantly Below Fair Value: INAF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INAF is unprofitable, so we can't compare its PE Ratio to the ID Pharmaceuticals industry average.
PE vs Market: INAF is unprofitable, so we can't compare its PE Ratio to the ID market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INAF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INAF is overvalued based on its PB Ratio (7.1x) compared to the ID Pharmaceuticals industry average (2.5x).
How is Indofarma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Indofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Indofarma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INAF is currently unprofitable.
Growing Profit Margin: INAF is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INAF is unprofitable, but has reduced losses over the past 5 years at a rate of 37.9% per year.
Accelerating Growth: Unable to compare INAF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INAF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.8%).
Return on Equity
High ROE: INAF has a negative Return on Equity (-7.39%), as it is currently unprofitable.
How is Indofarma's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: INAF's short term assets (IDR1,411.4B) exceed its short term liabilities (IDR1,045.2B).
Long Term Liabilities: INAF's short term assets (IDR1,411.4B) exceed its long term liabilities (IDR458.4B).
Debt to Equity History and Analysis
Debt Level: INAF's net debt to equity ratio (42.7%) is considered high.
Reducing Debt: INAF's debt to equity ratio has increased from 73.3% to 117.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable INAF has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: INAF is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 35.4% per year.
What is Indofarma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INAF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INAF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INAF's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INAF's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: INAF is not paying a notable dividend for the ID market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INAF has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Arief Pramuhanto (59 yo)
Mr. Arief Pramuhanto has been President Director of PT Indofarma (Persero) Tbk since May 7, 2019. Mr. Pramuhanto was General Affairs and Human Capital Director at PT Kimia Farma (Persero) Tbk since April 2...
CEO Compensation Analysis
Compensation vs Market: Arief's total compensation ($USD142.24K) is about average for companies of similar size in the ID market ($USD199.05K).
Compensation vs Earnings: Arief's compensation has increased whilst the company is unprofitable.
Experienced Management: INAF's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: INAF's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Indofarma Tbk's employee growth, exchange listings and data sources
- Name: PT Indofarma Tbk
- Ticker: INAF
- Exchange: IDX
- Founded: 1918
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp3.611t
- Shares outstanding: 3.10b
- Website: https://indofarma.id
Number of Employees
- PT Indofarma Tbk
- Jalan Indofarma No. 1
- Cikarang Barat
- Jawa Barat
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.